Please login to the form below

Not currently logged in
Email:
Password:

tau

This page shows the latest tau news and features for those working in and with pharma, biotech and healthcare.

Celgene bulks up pipeline again with $2.1bn Prothena deal

Celgene bulks up pipeline again with $2.1bn Prothena deal

The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);

Latest news

More from news
Approximately 3 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Acquisition company. 4, 800. Denali

  • Deal Watch - May 2017 Deal Watch - May 2017

    BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for  progressive supranuclear palsy.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    He believes that “tau has received nothing like the attention that amyloid has by big pharma - they all jump on the bandwagon, unfortunately. ... There are studies progressing with tau as a target, but it will be a while before clear evidence emerges.

  • Pharma deals in May 2015 Pharma deals in May 2015

    1, 100. Sigma Tau/ Baxter. Asset acquisition. Oncaspar (pegasparagase - marketed) portfolio in acute lymphoblastic leukaemia (ALL).

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Ryan brings over 15 years of central nervous system clinical research experience to the role, and takes on responsibility for Asceneuron's pipeline of innovative small molecules and progressing tau modifiers ... His outstanding track record and expertise

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Sigma-Tau Pharmaceuticals appoints CEO Sigma-Tau Pharmaceuticals appoints CEO

    Sigma-Tau Pharmaceuticals appoints CEO. Interim CEO Michael Minarich takes up the post in a permanent capacity. ... Rare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer.

  • EMA names new head of legal service EMA names new head of legal service

    An Italian national, Marino has extensive legal experience in the pahrma industry, having served as director of corporate legal and intellectual property at pharma firm Sigma-Tau since 1997.

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Forecasting in Forgotten Markets

    From a scientific perspective, the jury is still out on the root cause of these conditions and whether the current hypothesis around the involvement of Amyloid and Tau proteins in different

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics